Histogenics (HSGX) Misses Q4 EPS by 18c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Histogenics Corporation Announces Financial and Operating Results for the Fourth Quarter and Year Ended December 31, 2016
March 16, 2017 6:30 AM EDTNeoCart® Phase 3 Clinical Trial Enrollment on Track for Completion by End of Second Quarter of 2017 Strong Performance in all Areas of the Business in 2016 Financing Completed in the Third Quarter of 2016 Expected to Fund Company to Phase 3 Data Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT
WALTHAM, Mass., March 16, 2017 (GLOBE NEWSWIRE) -- Â Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced its financial and operational results for the year ended December 31, 2016.Â
... More